检索结果-南通市图书馆

Nanovectors for anti-cancer drug delivery in the treatment of advanced pancreatic adenocarcinoma

World Journal of Gastroenterology 2016年第31期22卷 7080-7090页

作者： Chung-Tzu Hsueh Julie H Selim James Y Tsai Chung-Tsen Hsueh Department of Dentistry Cathay General Hospital Division of Hematology/Oncology Loma Linda University Cancer Center School of Pharmacy Loma Linda University Division of Medical Oncology and Hematology Department of Internal Medicine Loma Linda University

Liposome, albumin and polymer polyethylene glycol are nanovector formulations successfully developed for anti-cancer drug delivery. There are significant differences in pharmacokinetics, efficacy and toxicity between pre- and post-nanovector modification. The alteration in clinical pharmacology is instrumental for the future development of nanovector-based anticancer therapeutics. We have reviewed the results of clinical studies and translational research in nanovectorbased anti-cancer therapeutics in advanced pancreatic adenocarcinoma, including nanoparticle albumin-bound paclitaxel and nanoliposomal irinotecan. Furthermore, we have appraised the ongoing studies incorporating novel agents with nanomedicines in the treatment of pancreatic adenocarcinoma.

关键词： Pancreatic adenocarcinoma Nanovector Nanoparticle albumin-bound paclitaxel nanoliposomal irinotecan Biomarker

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Modified FOLFIRINOX for resected pancreatic cancer: Opportunities and challenges

引用

World Journal of Gastroenterology 2019年第23期25卷 2839-2845页

作者： Feng Yang Chen Jin De-Liang Fu Andrew L Warshaw Department of Pancreatic Surgery Huashan HospitalFudan UniversityShanghai 200040China Department of Surgery Massachusetts General HospitalHarvard Medical SchoolBostonMA 02114United States

Pancreatic cancer is one of the leading causes of cancer death *** chemotherapy has been developed based on the experiences made with palliative chemotherapy, and advocated to improve long-term survival of patients with this disease. However, the optimal chemotherapeutic regimen remains controversial. Recently, Conroy et al demonstrated the impressive benefits of modified FOLFIRINOX over gemcitabine alone in the multicenter Partenariat de Recherche en Oncologie Digestive 24(PRODIGE-24) trial. The remarkable results mark a new milestone in treating resectable pancreatic cancer and have now changed the standard of care for this patient population. In this commentary, we discuss an issue of difference of tumor grade between the PRODIGE-24 trial and previous phase III trials. We also discuss potential biomarkers predicting therapeutic response to modified FOLFIRINOX. Finally,we summarize several ongoing clinical trials of replacing part of the FOLFIRINOX regimen with Xeloda/S-1/nanoliposomal irinotecan for pancreatic cancer.

关键词： Pancreatic cancer Adjuvant therapy FOLFIRINOX Neutrophil-tolymphocyte nanoliposomal irinotecan

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：